Abbisko Therapeutics Wins FDA Orphan Drug Designation for ABSK061 – Oral FGFR2/3 Inhibitor Targets Achondroplasia in Pediatric Patients
Abbisko Therapeutics Co., Ltd. (HKG: 2256) announced that ABSK061 received Orphan Drug Designation (ODD) from...
HKG: 2256
Abbisko’s Irpagratinib Doses First Patient in Phase II HCC Trial – FGFR4 Inhibitor Plus Toripalimab/Bevacizumab Targets First-Line Liver Cancer
Abbisko Therapeutics Co., Ltd (HKG: 2256) announced first patient dosing in a Phase II clinical...
Abbisko’s ABSK061 Wins FDA Rare Pediatric Disease Designation – FGFR2/3 Inhibitor Targets Achondroplasia
Abbisko Therapeutics Co., Ltd (HKG: 2256) announced that ABSK061, its self-developed highly selective small-molecule FGFR2/3...
Merck and Abbisko’s Pimicotinib NDA Accepted by FDA for TGCT, Building on China Approval
Merck KGaA (ETR: MRK) and Abbisko Therapeutics Co., Ltd. (HKG: 2256) announced that the U.S. FDA...
Abbisko ABSK043 NSCLC Combo Shows 71% Disease Control at ESMO Asia
Abbisko Cayman Limited (HKG: 2256) announced preliminary results from the dose escalation phase of the...
Abbisko ABSK141 KRAS-G12D Inhibitor Secures FDA IND Approval
Abbisko Cayman Limited (HKG: 2256) announced that its Investigational New Drug (IND) application for ABSK141,...
Abbisko Therapeutics Reports Durable Response in Phase 3 MANEUVER Study for Pimicotinib (ABSK021) in TGCT
Abbisko Therapeutics Co., Ltd. (HKG: 2256) released long‑term efficacy, safety and patient‑reported outcome data from its...
Abbisko’s ABSK043 Gains IND Approval for KRAS G12C NSCLC in Partnership with Allist
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) announced that the Center for Drug Evaluation...
Abbisko Therapeutics Completes First Patient Dosing for PRMT5×MTA Inhibitor ABSK131
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) announced the completion of the first patient...
Abbisko Therapeutics Launches Clinical Study of FGFR4 Inhibitor in Advanced Hepatocellular Carcinoma
Shanghai-based Abbisko Therapeutics Co., Ltd. (HKG: 2256) announced the dosing of the first patient in...
Abbisko Therapeutics’ FGFR4 Inhibitor Irpagratinib Granted Breakthrough Therapy Designation for HCC
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) announced that it has received Breakthrough Therapy...
Abbisko’s Pimitinib Granted Priority Review for TGCT Treatment in China
Abbisko Therapeutics Co., Ltd (HKG: 2256) announced that its self-developed, highly selective small-molecule CSF-1R inhibitor,...
Abbisko Therapeutics Secures $85M from Merck for Pimicotinib Global Rights
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) announced that its German partner Merck KGaA...
Abbisko Therapeutics Receives NMPA Approval for ACH Drug ABSK061
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced receiving clinical trial approval from...
Abbisko Therapeutics and Allist Pharmaceuticals Partner on KRAS-G12C NSCLC Combination Therapy
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has entered into a cooperation agreement with...
Abbisko Therapeutics’ ABSK131 Receives Clinical Trial Approval from China’s NMPA
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced receiving clinical trial approval from...
Abbisko Therapeutics Receives NMPA Approval for Irpagratinib Regulatory Study
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that it has received approval...
Abbisko Therapeutics Presents Positive Phase II Results for Pimicotinib in cGvHD at ASH
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) announced the presentation of preliminary Phase II...
Abbisko Therapeutics Gets FDA Green Light for Phase I Study of ABSK131 Inhibitor
Shanghai-based biotech company Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that it has received...
First Patient Dosed in Abbisko’s Phase II Trial of ABSK061 and ABSK043 in FGFR2/3 Altered Tumors
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced the first patient dosing in...